Search

Your search keyword '"Chen, Wenjia"' showing total 5 results
Start Over Author "Chen, Wenjia" Topic copd
5 results on '"Chen, Wenjia"'

3. Effects of β2‐Adrenergic Agonists on Risk of Parkinson's Disease in COPD: A Population‐Based Study.

Author

Chen, Wenjia, Sadatsafavi, Mohsen, Tavakoli, Hamid, Samii, Ali, and Etminan, Mahyar

Subjects
*PARKINSON'S disease, *OBSTRUCTIVE lung diseases, *INHALERS
Abstract

Introduction: Multiple studies have investigated the role of β2‐adrenoreceptor agonists on the risk of Parkinson's disease (PD). However, whether β2‐agonist use is associated with the risk of PD in patients with chronic obstructive pulmonary disease (COPD) has not been examined to date. Objectives: To examine the association between use of β2‐agonist and the risk of PD in patients with COPD. Methods: A case‐control study nested within a cohort of patients with COPD using the British Columbia health administrative databases from 1997 to 2015 was performed. Among a cohort of patients with COPD, all cases of PD were identified, and matched each case to up to five controls by age and calendar time. The use of β2‐agonists was assessed between the third and fourth year preceding the date of PD diagnosis, followed by additional two years of grace period (between the first and second year preceding PD incidence) to control for PD latency. The use of β2‐agonists was categorized into three levels: regular use (≥ 1 dispensation for every 6 months), irregular use (dispensation in one to three 6‐month periods), and no use. A conditional logistic regression model was used to estimate the rate ratio of PD according to β2‐agonist use, rigorously controlling for confounding variables. Results: Among 242,218 COPD patients, 732 PD cases and 3660 controls were identified. Use of β2‐agonists did not significantly affect the subsequent risk of PD (vs no use, adjusted rate ratios: regular use, 1.14 [95% CI: 0.93, 1.40, p=0.21], irregular use, 1.15 [95% CI: 0.92, 1.45, p=0.22]). Results remained consistent with competing risk sensitivity analysis. Conclusion: Use of β2‐agonists does not appear to affect the risk of PD in a real‐world COPD population. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

4. An Individualized Prediction Model for Long-term Lung Function Trajectory and Risk of COPD in the General Population.

Author

Chen, Wenjia, Sin, Don D., FitzGerald, J. Mark, Safari, Abdollah, Adibi, Amin, and Sadatsafavi, Mohsen

Subjects
*STANDARD deviations, *PREDICTION models, *LUNGS, *ALKALINE phosphatase, *TRIGLYCERIDES, *STATURE, *RESEARCH, *HEMATOCRIT, *BLOOD proteins, *AGE distribution, *RESEARCH methodology, *RESPIRATORY measurements, *EVALUATION research, *MEDICAL cooperation, *DYSPNEA, *BRONCHODILATOR agents, *RISK assessment, *SEX distribution, *SERUM albumin, *COMPARATIVE studies, *OBSTRUCTIVE lung diseases, *ALCOHOL drinking, *COUGH, *LEUKOCYTE count, *FORCED expiratory volume, *ELECTROCARDIOGRAPHY, *RESEARCH funding, *SPIROMETRY, *GLOBULINS, *ALGORITHMS, *LONGITUDINAL method
Abstract

Background: Prediction of future lung function will enable the identification of individuals at high risk of developing COPD, but the trajectory of lung function decline varies greatly among individuals. This study involved the development and validation of an individualized prediction model of lung function trajectory and risk of airflow limitation in the general population.Methods: Data were obtained from the Framingham Offspring Cohort, which included 4,167 participants ≥ 20 years of age and who had ≥ 2 valid spirometry assessments. The primary outcome was prebronchodilator FEV1; the secondary outcome was the risk of airflow limitation (defined as FEV1/FVC less than the lower limit of normal). Mixed effects regression models were developed for individualized prediction, and a machine learning algorithm was used to determine essential predictors. The model was validated in two large, independent multicenter cohorts (N = 2,075 and 12,913, respectively).Results: With 20 common predictors, the model explained 79% of the variation in FEV1 decline in the derivation cohort. In two validation datasets, the model had low error in predicting FEV1 decline (root mean square error range, 0.18-0.22 L) and high discriminative power in predicting risk of airflow limitation (C-statistic range, 0.86-0.87). This model was implemented in a freely accessible website-based application, which allows prediction based on flexible sets of predictors (http://resp.core.ubc.ca/ipress/FraminghamFEV1).Conclusions: The individualized predictor is an accurate tool to predict long-term lung function trajectories and risk of airflow limitation in the general population. This model enables identifying individuals at higher risk of COPD, who can then be targeted for preventive therapies. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

5. Mortality and acute exacerbation of COPD: a pilot study on the influence of myocardial injury

Author

Richard W. Troughton, Said Laribi, Erwin Hansconrad, Justina Motiejunaite, Mehmet Yilmaz, Christian Mueller, Semir Nouira, Kenan Ahmet Turkdogan, Agim Beshiri, Wenjia Chen, Zaid Sabti, Chris J. Pemberton, Alexandre Mebazaa, J. Mark FitzGerald, Jean-Marie Launay, Malha Sadoune, Lyndsey Kirwan, Mercedes Rivas-Lasarte, Corinne Collet, Patrick Plaisance, Mark Richards, Etienne Gayat, Biomarqueurs CArdioNeuroVASCulaires (BioCANVAS), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de Médecine d'Urgence [CHU Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Ecole de Médecine [Tours], Université de Tours (UT), Department of Medicine [Christchurch, New Zealand], University of Otago [Dunedin, Nouvelle-Zélande], Emergency Dept and Research Unit UR06SP21 [Monastir, Tunisia], CHU Fattouma Bourguiba [Monastir] (HFB), Department of Emergeny Medicine [Aydin, Turkey], Adnan Menderes Üniversitesi, Department of Cardiology [Sivas, Turkey], Cumhuriyet University [Sivas, Turkey], Université Sorbonne Paris Cité (USPC), Service d'Anesthésie-Réanimation [AP-HP Hôpitaux Saint-Louis Lariboisière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Cardiology Department [Barcelona, Spain], Hospital de la Santa Creu i Sant Pau, Department of Internal Medicine [Basel, Switzerland], University Hospital Basel [Basel], Département de Médecine d'Urgence [AP-HP Hôpitaux universitaires Saint-Louis, Lariboisière, Fernand-Widal], AP-HP Hôpitaux universitaires Saint-Louis, Lariboisière, Fernand-Widal, Department of Cardiology [Kaunas, Lithuania], Hospital of Lithuanian University of Health Sciences Kauno Klinikos [Kaunas, Lithuania], Medical and Scientific Affairs [Abbott Park, IL, USA], Abbott Laboratories, Respiratory Division [Vancouver, BC, Canada], University of British Columbia - UBC [Vancouver, BC, Canada], Service de Biochimie [AP-HP Hôpitaux Saint-Louis Lariboisière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], UBC and VGH Divisions of Respiratory Medicine [Vancouver, BC, Canada], St. Paul’s Hospital - University of British Columbia [Vancouver, BC, Canada]-Institute for Heart and Lung Health [Vancouver, BC, Canada], Cardiovascular Research Institute [Singapour], National University of Singapore (NUS), Vilnius University [Lithuania], This study was funded by ThermoFisher. A. Mebazaa and J. Motiejunaite would like to acknowledgethe support of the Research Council of Lithuania, grant number MIP-049/2015., Université Paris Diderot - Paris 7 (UPD7), Service de biochimie INSERM UMR-S942, Hôpital Lariboisière-APHP, Service des Urgences, Hôpital Lariboisière, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Institut fuer Theoretische Physik (Institut fuer Theoretische Physik), Universität Heidelberg [Heidelberg], U942, Hop Lariboisiere, AP HP,Dept Biochem, Institut National de la Santé et de la Recherche Médicale (INSERM), Département d'Anesthésie Réanimation SMUR [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], St. Paul’s Hospital - University of British Columbia [Vancouver, BC, Canada] (SPH-UBC)-Institute for Heart and Lung Health [Vancouver, BC, Canada], Mebazaa, Alexandre, Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Université de Tours, Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), [Laribi, Said] Francois Rabelais Univ, Sch Med, Tours, France -- [Laribi, Said] Tours Univ Hosp, Emergency Med Dept, Tours, France -- [Laribi, Said -- Kirwan, Lyndsey -- Gayat, Etienne -- Rivas-Lasarte, Mercedes -- Sadoune, Malha -- Motiejunaite, Justina -- Plaisance, Patrick -- Launay, Jean-Marie -- Mebazaa, Alexandre] INSERM, U942, BIOmarkers CArdioNeuroVASc Dis, Paris, France -- [Pemberton, Chris J. -- Troughton, Richard W. -- Richards, Mark] Univ Otago, Dept Med, Christchurch Heart Inst, Christchurch, New Zealand -- [Nouira, Semir] Fattouma Bourguiba Univ Hosp, Emergency Dept, Monastir, Tunisia -- [Nouira, Semir] Fattouma Bourguiba Univ Hosp, Res Unit UR06SP21, Monastir, Tunisia -- [Turkdogan, Kenan] Adnan Menderes Univ, Fac Med, Dept Emergeny Med, Aydin, Turkey -- [Yilmaz, Mehmet Birhan] Cumhuriyet Univ, Fac Med, Dept Cardiol, Sivas, Turkey -- [Gayat, Etienne -- Plaisance, Patrick -- Mebazaa, Alexandre] Univ Paris Diderot, Sorbonne Paris Cite, Paris, France -- [Gayat, Etienne -- Motiejunaite, Justina -- Mebazaa, Alexandre] St Louis Lariboisiere Hosp, AP HP, Dept Anesthesiol & Crit Care, Paris, France -- [Rivas-Lasarte, Mercedes] Univ Autonoma Barcelona, Biomed Res Inst IIB St Pau, Hosp Santa CreuiSt Pau, Cardiol Dept, Barcelona, Spain -- [Sabti, Zaid -- Mueller, Christian] Univ Hosp, Dept Internal Med, Basel, Switzerland -- [Hansconrad, Erwin -- Plaisance, Patrick] St Louis Lariboisiere Hosp, AP HP, Emergency Med Dept, Paris, France -- [Motiejunaite, Justina] Lithuanian Univ Hlth Sci Kauno Klinikos, Dept Cardiol, Kaunas, Lithuania -- [Beshiri, Agim] Abbott Labs, Abbott Pk, IL 60064 USA -- [Chen, Wenjia] Univ British Columbia, Resp Div, Inst Heart & Lung Hlth, Vancouver, BC, Canada -- [Collet, Corinne] St Louis Lariboisiere Hosp, AP HP, Dept Biochem, Paris, France -- [FitzGerald, J. Mark] Inst Heart & Lung Hlth, UBC Div Resp Med, Vancouver, BC, Canada -- [FitzGerald, J. Mark] Inst Heart & Lung Hlth, VGH Div Resp Med, Vancouver, BC, Canada -- [Richards, Mark] Natl Univ Singapore, Cardiovasc Res Inst, Singapore, Singapore -- [Mebazaa, Alexandre] Vilnius Univ, Vilnius, Lithuania, YILMAZ, Mehmet Birhan -- 0000-0002-8169-8628, YILMAZ, MEHMET BIRHAN -- 0000-0002-8169-8628, Chen, Wenjia -- 0000-0001-8201-7145, GAYAT, Etienne -- 0000-0002-3334-3849, Mebazaa, Alexandre -- 0000-0001-8715-7753, and collet, corinne -- 0000-0001-6990-863X

Subjects
Male, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Exacerbation, [SDV]Life Sciences [q-bio], Pilot Projects, 030204 cardiovascular system & hematology, Severity of Illness Index, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, law.invention, Cohort Studies, Pulmonary Disease, Chronic Obstructive, 03 medical and health sciences, 0302 clinical medicine, Copeptin, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Interquartile range, law, Internal medicine, Natriuretic Peptide, Brain, medicine, Humans, Myocardial infarction, Intensive care medicine, ComputingMilieux_MISCELLANEOUS, Aged, COPD, business.industry, Myocardium, Mortality rate, Glycopeptides, Middle Aged, Prognosis, medicine.disease, Intensive care unit, Troponin, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, 3. Good health, 030228 respiratory system, Cohort, Regression Analysis, [SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, Female, Cardiomyopathies, business, Biomarkers
Abstract

WOS: 000404447400031, PubMed ID: 28663316, …, ThermoFisher; Research Council of Lithuania [MIP-049/2015]; Crossref Funder Registry, This study was funded by ThermoFisher. A. Mebazaa and J. Motiejunaite would like to acknowledge the support of the Research Council of Lithuania, grant number MIP-049/2015. Funding information for this article has been deposited with the Crossref Funder Registry.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results